Current drug delivery · 2007
RNAi silencing in mouse models of neurodegenerative diseases.
СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Farah Mohamed H
Аннотация
RNA interference (RNAi) has emerged as a potential therapeutic approach for neurodegenerative diseases, particularly those associated with autosomal dominant patterns of inheritance. In proof of concept experiments, several groups have demonstrated efficacy of using viral vectors expressing short hairpin RNA (shRNA) directed against therapeutically relevant genes in mouse models of neurodegenerative diseases, including spinocerebellar ataxia, Amyotrophic Lateral Sclerosis, Huntington's Disease and amyloidosis (a pathological aspect of Alzheimer's Disease). Although viral-based RNAi has limitations that most likely will preclude its usage in humans, a few recent developments underscore the potential of non-viral-based delivery of relevant RNAi as therapeutics for neurodegenerative diseases. Here, I will review the recent literature on effectiveness of RNAi as a therapeutic strategy in mouse models of neurodegenerative diseases.
Предметные рубрики MeSH
Alzheimer DiseaseAmyloid Precursor Protein SecretasesAmyloidosisAmyotrophic Lateral SclerosisAnimalsAspartic Acid EndopeptidasesAtaxin-1AtaxinsBlood-Brain BarrierDisease Models, AnimalGene Transfer TechniquesGenetic TherapyGenetic VectorsHuntingtin ProteinHuntington DiseaseMiceNerve Tissue ProteinsNeurodegenerative DiseasesNuclear ProteinsRNA InterferenceRNA, Double-StrandedRNA, Small InterferingSpinocerebellar AtaxiasSuperoxide DismutaseSuperoxide Dismutase-1